Insights

Key opinion leaders discuss recent updates in treating relapsed or refractory multiple myeloma.

Recommendations for appropriately managing metastatic colorectal cancer with anti-EGFR therapy based on recent changes to cetuximab dosing.

Recommendations for sequencing therapies for triple-class refractory myeloma with options such as selinexor, belantamab mafodotin, or melflufen.

Experts in hematology and medical oncology, Anthony Mato, MD, MSCE, and Lori A. Leslie, MD, discuss the current therapeutic options available for marginal zone lymphoma and follicular lymphoma and provide key insights into how the recent accelerated approval of umbralisib has impacted the treatment landscape.

Experts in gynecologic oncology review key advances in treating advanced endometrial cancer and the promise of combination immunotherapy-based regimens.

Corey S. Cutler, MD, MPH, FRCPC; Yi-Bin Chen, MD; and Haris Ali, MD, review currently available treatment options for acute and chronic GVHD and discuss the management of steroid-refractory disease.